VYNE Therapeutics Inc. (NASDAQ:VYNE) Sees Significant Growth in Short Interest

VYNE Therapeutics Inc. (NASDAQ:VYNE) saw a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 183,974 shares, a growth of 76.3% from the June 30th total of 104,336 shares. Approximately 0.6% of the company’s shares are sold short. Based on an average trading volume of 2,270,132 shares, the short-interest ratio is presently 0.1 days.

VYNE Therapeutics Price Performance

Shares of VYNE stock opened at $28.32 on Thursday. The stock has a market cap of $18.98 million, a PE ratio of -74.54 and a beta of 2.00. The stock has a 50-day moving average of $33.82 and a 200-day moving average of $31.49. VYNE Therapeutics has a one year low of $14.03 and a one year high of $79.75.

VYNE Therapeutics (NASDAQ:VYNE) last released its quarterly earnings data on Friday, May 15th. The company reported ($4.00) earnings per share for the quarter, topping the consensus estimate of ($9.00) by $5.00. VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%. The business had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.20 million.

VYNE Therapeutics Announces Dividend

The company also recently announced a special dividend, which was paid on Thursday, July 23rd. Shareholders of record on Wednesday, July 22nd were issued a $19.00 dividend.

Institutional Trading of VYNE Therapeutics

A number of large investors have recently made changes to their positions in VYNE. ADAR1 Capital Management LLC lifted its holdings in VYNE Therapeutics by 319.2% during the first quarter. ADAR1 Capital Management LLC now owns 1,063,899 shares of the company’s stock worth $636,000 after acquiring an additional 810,108 shares in the last quarter. Rangeley Capital LLC raised its position in shares of VYNE Therapeutics by 18.1% during the first quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock worth $71,000 after purchasing an additional 18,064 shares during the period. KVP Capital Advisors LP bought a new position in shares of VYNE Therapeutics during the 4th quarter valued at about $290,000. XTX Topco Ltd acquired a new position in shares of VYNE Therapeutics in the 4th quarter valued at approximately $46,000. Finally, Anson Funds Management LP bought a new stake in VYNE Therapeutics during the 4th quarter worth approximately $739,000. Institutional investors own 83.78% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of VYNE Therapeutics in a research report on Monday, May 4th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Reduce”.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.